Lixte Biotechnology Holdings, Inc. (LIXT)
NASDAQ: LIXT · Real-Time Price · USD
3.300
-0.670 (-16.88%)
At close: Jul 14, 2025, 4:00 PM
3.442
+0.142 (4.29%)
After-hours: Jul 14, 2025, 4:17 PM EDT
LIXT Employees
Lixte Biotechnology Holdings had 2 employees as of December 31, 2024. The number of employees decreased by 2 or -50.00% compared to the previous year.
Employees
2
Change (1Y)
-2
Growth (1Y)
-50.00%
Revenue / Employee
n/a
Profits / Employee
-$1,662,099
Market Cap
9.07M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LIXT News
- 4 days ago - Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $1.5 Million Registered Direct Offering - GlobeNewsWire
- 5 days ago - New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials - GlobeNewsWire
- 6 days ago - Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $5.0 Million Private Placement - GlobeNewsWire
- 12 days ago - Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market - GlobeNewsWire
- 13 days ago - Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market - GlobeNewsWire
- 3 months ago - LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100 - GlobeNewsWire
- 3 months ago - LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer - GlobeNewsWire
- 4 months ago - LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer - GlobeNewsWire